Theorem Clinical Research, Charles River Form Strategic Alliance
Theorem Clinical Research has announced the formation of a strategic alliance with Charles River Laboratories that will provide clients with an integrated solution from nonclinical testing and analysis through clinical development and registration.
Theorem Clinical Research
has announced the formation of a strategic alliance with
Charles River Laboratories
that will provide clients with an integrated solution from nonclinical testing and analysis through clinical development and registration. The new alliance provides nonclinical testing programs in the areas of bioanalysis, immunogenicity and immunology to support clinical trials.
“Charles River develops and validates assays in support of nonclinical programs, and many of these assays can be validated for human matrix and used for analyzing clinical samples,” said
Dr. Marc Hoffman
, Theorem senior vice president and general manager of
biopharmaceutical development
.
Charles River’s
high-quality research models
, preclinical testing capabilities and clinical support services are backed by a comprehensive bioanalysis portfolio for non-GLP and GLP programs. Laboratories are equipped with the latest instrumentation to measure drug and metabolite concentrations in biological matrices and to provide full support for capillary micro sampling and dried blood spot analysis. The variety of advanced equipment ensures the capacity to meet critical deadlines.
“We are pleased to partner with a world-class clinical trials organization like Theorem Clinical Research. Sponsors will benefit from the experience of both organizations. The alliance will offer a seamless transition from preclinical testing into the clinical arena,” said Alan Bartlett, executive director of laboratory services,
Charles River Laboratories
.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
